Sununary Menogaril is an anthracycline presently in Phase II clinical trials. Menogaril-resistant mouse leukaemia P388 cells were developed in vitro by 4 months of exposure to step-wise increasing concentrations of menogaril after which resistant cells (P388/MEN) were cloned in 320 ng ml-' menogaril. P388/MEN cells were 40-fold more resistant to menogaril in vitro compared to P388/0 and were also resistant in vivo. Resistance to menogaril was stable for at least 2 months in the absence of the drug. The (Li et al., 1979) ; adriamycin interacted strongly with DNA, whereas menogaril interacts weakly (Li et al., 1979) ; S phase cells were most sensitive to adriamycin, whereas G, cells were most sensitive to menogaril (Bhuyan et al., 1980) . These results collectively suggest that menogaril acts through some mechanism other than the intercalative DNA binding proposed for adriamycin.
Menogaril, also known as 7-OMEN, menogarol, or 7-(R)-0-methylnogarol, is an anthracycline in Phase II clinical trials (Stemnberg et al., 1986) . It entered clinical trial by virtue of its broad spectrum of antitumour activity against transplantable animal tumours even when given orally (McGovren, 1980) , its activity against human tumour cells in the cloning assay (Weiss et al., 1983) , a lower potential for cardiotoxicity ) and a site of action different from that of adriamycin (Bhuyan et al., 1980; Li et al., 1979) . The biochemical activity of adriamycin and menogaril are markedly different in the following respects: at cytotoxic doses, adriamycin inhibited RNA synthesis more than DNA synthesis in L1210 cells in culture, whereas menogaril caused very little inhibition of RNA or DNA synthesis at cytotoxic doses (Li et al., 1979) ; adriamycin interacted strongly with DNA, whereas menogaril interacts weakly (Li et al., 1979) ; S phase cells were most sensitive to adriamycin, whereas G, cells were most sensitive to menogaril (Bhuyan et al., 1980) . These results collectively suggest that menogaril acts through some mechanism other than the intercalative DNA binding proposed for adriamycin.
The development of a population of cells within a tumour resistant to antineoplastic agents is of obvious clinical significance. In many cases, as was documented with adriamycin, development of resistance to one drug was associated with cross-resistance to several structurally unrelated drugs (Kartner et al., 1983; Schabel et al., 1983; Johnson et al., 1978; Kaye and Merry, 1985) . This multidrug resistant phenotype was shown to include: cross-resistance to structurally unrelated agents (Kartner et al., 1983) ; reversal of resistance with verapamil (Klohs et al., 1986) ; decreased intracellular drug concentration by decreased drug uptake, or increased efflux (Ling & Thompson, 1974) ; and amplification or overexpression of one or more mdr associated genes (Riordan et al., 1985) . Because menogaril is an anthracycline similar in structure to adriamycin, it is of clinical significance to find out if menogaril-resistant cells are also pleiotropically resistant. Our results show that the phenotypes of menogariland adriamycin-resistant P388 cells are different. Parts of this paper were previously presented as an abstract (Badiner & Bhuyan, 1986a; Moy et al., 1986) .
Materials and methods

Methods
Cell culture conditions and characterisations P388 cells were obtained from NCI-Frederick (Frederick, MD 21707) . Adriamycin-resistant P388 (P388/Adr) were obtained from Southern Research Institute (Birmingham AL 35255). Cells were grown in vitro in RPMI 1640 with 5% FCS in a 5% CO2 humidified incubator and maintained in exponential growth by subculturing prior to 5 x 105cells/ml. Chinese hamster CHrC5 and AuxB, cell lines were obtained from I.
Abraham (The Upjohn Company, Kalamazoo, MI 49001) and maintained as previously described (Bech-Hansen et al., 1975) . Cells were suspended in growth medium with 7% DMSO and then frozen in liquid nitrogen. All cell stocks were free of Mycoplasma contamination. Stocks removed from liquid nitrogen were passaged in vitro for 2 weeks before experimental use. Cells were karyotyped and isozyme patterns were determined by Dr. Ward Peterson (Children's Hospital, Detroit, MI) using standard techniques (Ottenbreit et al., 1983; Peterson et al., 1979) .
Resistance development protocol was as follows. P388 cells were maintained at I0O cells ml-' x 500 ml in a 1 I Bellco roller bottle (Bellco, Vineland, NJ Cell survival after drug exposure was determined by cloning in soft agar medium, as described in detail previously (Badiner et al., 1987b (Gros et al., 1986) . The probe was labelled with 32P by nick translation. Washed membranes were exposed for 4-16 h at -70°C to Kodak X-Omat AR film with an intensifying screen.
Total cellular RNA was isolated as previously described (Chirgwin et al., 1979) . RNA (10 Mg) was dissolved in buffer (3.42 MlI glyoxal, 30ML 1 M sodium phosphate -pH 6.8, 1.5 ml DMSO, 30Ml 10% SDS and 100Mil water) and electrophoresed in a 1.5% agarose gel with recirculated 10 mM sodium phosphate running buffer. Fractionated RNA was transferred to a Nytran membrane by electroblotting overnight at 20 volts and 4'C. The blots were washed in 6 x SSC and then crosslinked with u.v. The 1.6 kbp insert from the plasmid pDR 1.6 (Gros et al., 1986) was isolated and labelled with 32P by random priming (Feinberg & Vogelstein, 1984 Cells growing in 0.32 pg ml-' menogaril were cloned in soft agar medium and 20 clones were isolated. The clones had similar doubling times (20-27 h) and sensitivities in the growth inhibition assay (ID,o values range 0.5-0.7 Lsgml-').
However, significant differences were seen in their cloning efficiency in soft agar (range from 25 to 66%) and one clone failed to grow. The clones also differed in their survival after drug exposure, e.g., at 0.32 jig ml-' menogaril, the survival ranged from 30-100%. Clone 13 was selected for further study because of its high cloning efficiency (66%) and high level of drug resistance and was designated P388/MEN. Ten P388/0 clones were also examined and no significant differences were seen among these clones in growth rate, clonogenicity in soft agar and ID_o or LD^o values after exposure to menogaril (data not shown).
Cell morphology and electron microscope studies The P388/0 and P388/Adr cell lines grew as single cell suspension with relatively few cell aggregates. All of the menogaril-resistant clones formed dense cellular aggregates which were easily dispersed with a pipette. Cell surface morphology, as demonstrated by scanning electron micropscopy, did not show any significant differences between the sensitive and resistant P388 cell lines.
Isozyme and karyotype analysis of P388 and P388/MEN cells show minor differences Isozyme analysis of G6PD, LDH, MDH and NP present in cell extracts from P388/0 and P388/MEN cell lines showed these to be of mouse origin.
Karyotypes of P388/0 and P388/MEN were determined and the results are described below. P388/0 had chromosomes typical of mouse origin with 85 of 100 metaphases having 36-40 chromosomes (2N = 40) and 15 metaphases with 79 chromosomes. One marker chromosome (M 1) present in all P388/0 karyotypes was a #2 chromosome with an insertion in the B region. P388/MEN also contained typical mouse chromosomes with 89 of 100 metaphases having 36-40 chromosomes and 11 metaphases with 79 chromosomes. Two marker chromosomes were noted in P388/MEN. The first marker chromosome (M1) was the same as noted for P388/0, the second marker was a # I chromosome with a variable staining HSR segment attached to the p arm and occurred in 50% of the karyotypes examined. P388/MEN had three double minutes in the 30 metaphases examined, P388/0 had a minute chromosome in 2 of 30 metaphases examined. These results show no significant difference between the sensitive and resistant cell lines in modal number or minute chromosomes, with very few double minutes in P388/MEN. P388/MEN and P388/ADR demonstrate different cross resistance patterns Growth inhibition assay (ID_0) showed P388/ MEN was 40-fold more resistant to menogaril than the sensitive P388/0 cells and was cross-resistant (i.e., 60-fold more resistant) to adriamycin. P388/MEN was not crossresistant to Velban and actinomycin D, and was collaterally sensitive to cisplatin (Table I ) compared to P388/0. In contrast, P388/ADR was cross-resistant to all these components.
Verapamil does not reverse menogaril resistance in P388/MEN cells Verapamil has been shown to reverse adriamycin resistance by decreasing drug efflux, presumably by verapamil binding to the efflux pump, gp 170 (Riordan et al., 1985) . Therefore, we tested the ability of verapamil to reverse the growth inhibition by menogaril of P388/0, P388/MEN and P388/Adr cells (Figure 2a) . Figure 2b shows the response of these cells to adriamycin, with or without verapamil. Figure  2a shows that verapamil did not affect growth inhibition by menogaril of P388/MEN (compare O,) or P388/0 (compare 0,0) which suggests that menogaril resistance was not mediated through increased drug efflux by gp 170. But, in agreement with the observation of Harker & Sikic (1985) , verapamil increased growth inhibition by adriamycin of P388/Adr (Figure 2b compare A,A) . Thus, 0.5 ttg ml-' adriamycin inhibited growth of P388/Adr only 10% as compared to 90% inhibition in the presence of verapamil. This confirms that adriamycin resistance in P388/Adr was mediated through increased drug efflux by gp 170. Figure 2b shows that, at the 50% inhibition level, there was a 2-fold increase in sensitivity of both P388/MEN (compare 0,E) and P388/0 (compare 0,0) to adriamycin in the presence of verapamil compared to its absence. P388/Adr was 2-fold more sensitive to menogaril in the presence of verapamil (Figure 2a (Green et al., 1984; Hamilton et al., 1985) . Also, lowering GSH levels by pretreating cells with buthionine sulfoximine potentiated adriamycin cytotoxicity in human ovarian and breast tumour cell lines (Hamilton et a!., 1985; Dusre et al., 1989 ). Therefore, we tested whether GSH was involved in menogaril resistance. For this purpose, we compared GSH levels in sensitive and resistant cell lines and also determined whether buthionine sulfoximine treatment can potentiate menogaril toxicity. 
Discussion
Resistance of P398 cells to menogaril was achieved by continuous exposure of the suspension culture to increasing drug concentrations. We also used an alternate method of selecting drug-resistant cells by cloning viable cells in soft agar at each step of increasing drug level. This method worked well but did not generate a resistant population any faster than the present method. It should be noted that potent mutagens were not used to generate resistant variants. As the culture adapted to continuous drug exposure, the time between stepwise increase in drug dose decreased, i.e., resistance developed faster. Rapid increase in resistance at the later stages was also reported by Beran & Anderson (1987) during development of resistance to m-AMSA. Lower drug uptake and/or more efficient efflux often account for the lower drug sensitivity of the resistant cell line (Harker & Sikic, 1985) . However, it is difficult to decide what dose of drug to use in uptake experiments since the sensitive and resistant cell lines are so different in their drug sensitivity. The dose should be high enough to cause significant cytoxicity without damaging the efflux mechanism. At 0.3 sg ml1' menogaril, which is the LD90 for P388/0 and nontoxic to P388/MEN, the difference in uptake and efflux between the 2 cell lines was small. At 1 ggml m1', which is highly toxic (> LDg9) to P388/0, efflux was very slow, probably because the efflux mechanism was damaged. However, efflux was normal at the I fig ml' dose in P388/MEN, although it was inhibited at 8 1g ml-'. Based on the results at 0.3 jig ml-' we concluded that uptake and efflux differences are not likely to explain the difference in sensitivity between P388/0 and P388/MEN.
Gene amplification in drug resistant cell lines has been correlated with the appearance of double minutes and HSR in the karyotypes (Robertson et al., 1984) . P388/0 and P388/ MEN had very similar karyotypes with the resistant line having an extra marker chromosome which did have a somewhat variable HSR. It is unlikely that the HSR or small number of double minutes can account for menogaril resistance. This is based on our observation that P388/MEN cells fused with S49 mouse lymphoma cells retain menogaril resistance but do not have the HSR (Badiner et al., 1986b) .
P388/MEN cells did not meet the established criteria for the multidrug resistant phenotype as seen for other anthracycline resistant cells (Robertson et al., 1984; Kartner et al., 1983 Danks et al. (1987) reported the 'atypical' multidrug resistance characteristics of a teniposide (VM-26) resistant human leukaemic (CEM) cell line. They showed that drug resistance was not due to P-glycoprotein-mediated decreased intracellular drug concentration but was probably due to altered interaction between drug and cellular target. Slovak et al. (1988) also reported different mechanisms of Adr resistance in 2 human cell lines. Adr resistance in LoVo cells correlated with P-glycoprotein increase whereas a non-P-glycoprotein mediated mechanism operated in HT1080 cells. Resistance to Adr can be multifactorial and result from decreased drug uptake, decreased formation of DNA strand breaks and early onset of repair, increased glutathione transferase activity and elevated P-glycoprotein activity (Deffie et al., 1988) . Reduced topoisomerase activity has also been reported to correlate with Adr resistance (Deffie et al., 1989) . It is possible that some of these mechanisms may account for menogaril resistance.
Our results clearly show that GSH is not likely to be involved in menogaril resistance in P388/MEN cells. GSH content of P388/MEN cells was not increased over that of the sensitive cell line and the cytotoxicity of menogaril was not potentiated when GSH concentration was lowered by pretreatment with buthionine sulfoximine. Our results suggest that GSH may be involved in adriamycin resistance of P388/ ADR cells. P388/ADR cells contained twice as much GSH as the sensitive cell line and lowering GSH content potentiated adriamycin toxicity about 1.5-fold. The GSH content of our P388/0 cells was similar to that reported by Ramu et al. (1984) . They also observed a 1.5-fold increase in GSH and GSH-peroxidase content of P388/ADR cells over that of the sensitive cells. However, they did not see any potentiation of drug cytotoxicity when P388/ADR cells were treated with adriamycin after glutathione depletion by 1-chloro-2,4-dinitrobenzene. Potentiation of adriamycin cytotoxicity by GSH depletion has been reported for human tumour cell lines. Hamilton et al. (1985) reported that in both sensitive and adriamycin-resistant ovarian carcinoma cell lines GSH depletion potentiated adriamycin cytotoxicity. Dusre et al. (1989) also reported potentiation of adriamycin cytoxicity in multidrug resistant human breast tumour cells. The phenotype of the resistant cell line depends on the cell line and the drug to which it is resistant. The same cell line, P388, made resistant to two different anthracyclines (menogaril or adriamycin) displayed different phenotypes. P388/MEN had a non-multidrug resistant phenotype while P388/ADR fit the established criteria for the MDR phenotype. When the same drug, menogaril, was used to develop two different resistant cell lines, P388/MEN and (Chinese hamster) V79/MEN, the phenotypes were again different. P388/MEN had a nonmultidrug resistant phenotype whereas V79/MEN cells had the MDR phenotype (Badiner et al., 1987a) .
In the light of the difference between P388/MEN and V79/MEN, the clonal heterogeneity of P388/MEN, as expressed by differences in clonogenicity and differences in the level of resistance to menogaril become interesting. The clonal heterogeneity may indicate the existence in P388/MEN of a variety of resistance mechanisms, some of which may be of the MDR type. Such information may be relevant to clinical evaluation of menogaril. The P388/MEN tumour was refractory to therapeutic doses of menogaril and this resistance was stable for at least 12 weeks in vivo. Further studies on the in vivo cross-resistance pattern of P388/MEN show interesting differences from that seen in vitro (Badiner et al., 1987c) . These observations may be important in the selection of appropriate cell lines for the study of drug resistance.
